The global vascular stents market is experiencing robust growth, driven by the rising prevalence of cardiovascular diseases, an aging population, and continuous technological advancements. In 2024, the market reached a value of USD 11.2 billion and is projected to expand to USD 17.5 billion by 2033, exhibiting a CAGR of 5.1% during the forecast period. The increasing demand for minimally invasive procedures and the development of innovative stent technologies are key factors propelling this growth.
Study Assumption Years
- Base Year: 2024
- Historical Years: 2019–2024
- Forecast Years: 2025–2033
Vascular Stents Market Key Takeaways
- Market Size and Growth: The vascular stents market was valued at USD 11.2 billion in 2024 and is expected to reach USD 17.5 billion by 2033, growing at a CAGR of 5.1% from 2025 to 2033.
- Product Segmentation: Coronary stents dominate the market, addressing the high incidence of coronary artery diseases.
- Material Preference: Metallic stents, particularly those made from cobalt chromium and stainless steel, hold the largest market share due to their durability and biocompatibility.
- Mode of Delivery: Balloon-expandable stents are the leading segment, favored for their precision in placement during procedures.
- End-User Insights: Hospitals and cardiac centers are the primary end-users, attributed to their advanced infrastructure and specialized cardiac care units.
- Regional Performance: North America leads the market, supported by a well-established healthcare system and high adoption of advanced stent technologies.
Market Growth Factors
1. Rising Prevalence of Cardiovascular Diseases
The rising prevalence of cardiovascular diseases like coronary artery disease and peripheral artery disease worldwide is a key factor propelling the vascular stents market. Factors such as sedentary lifestyles, poor diets, and an aging population are fueling the increasing occurrence of these conditions. Vascular stents are vital in unblocking or widening arteries to facilitate blood flow, providing a minimally invasive remedy for patients. With the escalating burden of cardiovascular diseases, the need for efficient treatments like vascular stents is projected to increase in tandem.
2. Technological Advancements and Product Innovations
Continuous innovations in stent technology have enhanced the safety and effectiveness of vascular stents. The introduction of drug-eluting stents (DES) and bioabsorbable stents has notably improved patient outcomes by lowering the risk of restenosis and reducing long-term complications. Progress in stent materials, designs, and coatings further enhances performance and patient compatibility, making vascular stents more effective and broadening their application across different vascular conditions.
3. Aging Population and Increased Longevity
The increasing number of elderly people around the world is another important reason why the vascular stents market is growing. Older individuals are more prone to vascular diseases, which require effective treatment options. Vascular stents, particularly advanced types like drug-eluting and bioabsorbable stents, provide minimally invasive solutions that are especially advantageous for older patients. With longer life expectancies, it is expected that the need for these medical procedures will increase, driving further growth in the market.
Request for a sample copy of this report: https://www.imarcgroup.com/vascular-stents-market/requestsample
Market Segmentation
Breakup by Product Type
- Coronary Stents: Used to treat blockages in the coronary arteries, these stents are essential in managing coronary artery disease.
- Peripheral Vascular Stents: Designed for arteries outside the heart, such as those in the limbs, these stents address peripheral artery disease.
- EVAR Stent Grafts: Employed in endovascular aneurysm repair, these stent grafts reinforce weakened sections of the aorta to prevent aneurysm rupture.
Breakup by Material
- Metallic Stents:
- Cobalt Chromium: Known for high strength and radiopacity, enhancing visibility during imaging.
- Platinum Chromium: Offers excellent flexibility and conformability to vessel anatomy.
- Nickel Titanium (Nitinol): Provides superelasticity and shape memory, ideal for self-expanding stents.
- Stainless Steel: Offers durability and cost-effectiveness, commonly used in bare-metal stents.
- Others: Includes polymer-based and bioresorbable materials offering temporary support and reduced long-term complications.
Breakup by Mode of Delivery
- Balloon-Expandable Stents: Expanded using a balloon catheter, allowing precise placement, commonly used in coronary arteries.
- Self-Expanding Stents: Made from materials like Nitinol, these stents expand automatically upon deployment, suitable for peripheral arteries.
Breakup by End-User
- Hospitals and Cardiac Centers: Primary facilities for complex cardiovascular procedures, equipped with advanced infrastructure and specialized personnel.
- Ambulatory Surgical Centers: Offer outpatient procedures, providing cost-effective and convenient options for patients undergoing less complex interventions.
Breakup by Region
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Regional Insights
North America’s basically running the show when it comes to vascular stents. Why? Well, for starters, the healthcare game over there is strong—like, everyone’s spending big on medicine, hospitals are tricked out with the latest tech, and unfortunately, a lotta folks deal with heart problems. Add in all the major companies hustling new stent gadgets every other week, and it’s honestly no surprise they’re leading the pack.
Recent Developments & News
- May 13, 2022: Medtronic Plc received FDA approval for the Onyx Frontier™ drug-eluting stent (DES), featuring an enhanced delivery system for improved performance in complex cases.
- October 6, 2021: Boston Scientific Corporation presented positive clinical trial data for the Eluvia™ Drug-Eluting Vascular Stent System, demonstrating superiority over bare-metal stents in treating peripheral artery disease.
- December 17, 2020: MicroPort NeuroTech Co., Ltd. obtained regulatory approval in China for the Bridge® Vertebral Drug-Eluting Stent, designed for treating symptomatic vertebral artery stenosis.
Key Players
- Medtronic Plc
- Abbott Laboratories
- Boston Scientific Corporation
- Biotronik SE & Co. KG
- B. Braun Melsungen AG
- Terumo Corporation
- MicroPort Scientific Corporation
- Meril Life Sciences Pvt. Ltd.
- Vascular Concepts Limited
- C.R. Bard, Inc.
- W.L. Gore and Associates, Inc.
- Endologix, Inc.
- Lombard Medical
- Translumina GmbH
- Jotec GmbH
Ask Analyst for Customization: https://www.imarcgroup.com/request?type=report&id=1382&flag=C
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include a thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape, and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: +1-631-791-1145
